Search results for " BCR-ABL Positive"

showing 10 items of 57 documents

Differences among young adults, adults and elderly chronic myeloid leukemia patients

2014

Abstract BACKGROUND: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. PATIENTS AND METHODS: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CML WP over a 40-year period. RESULTS: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old)…

MalePediatricsHost responseBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Oncology; HematologyTyrosine kinase inhibitorDiseaseAntineoplastic AgentTyrosin kinase inhibitorProtein-Tyrosine Kinasehemic and lymphatic diseases80 and overAge FactorProspective StudiesYoung adultChronicBCR-ABLAged 80 and overLeukemiaIncidence (epidemiology)Chronic myeloid leukemiaAge FactorsMyeloid leukemiaHematologyMiddle AgedProtein-Tyrosine KinasesPrognosisLeukemiaOncologybcr-abl1FemaleBCR-ABL; chronic myeloid leukemia; prognosis; tyrosine kinase inhibitors; young adultsHumanAdultyoung adultsmedicine.medical_specialtyPrognosiProtein Kinase InhibitorAntineoplastic Agentschronic myeloid leukemia; bcr-abl1; Tyrosin kinase inhibitor; prognosis; young adultsNOYoung Adultchronic myeloid leukemiaLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young AdultProtein Kinase InhibitorsAgedTyrosine kinase inhibitorsAdult patientsbusiness.industrymedicine.diseaseClinical trialBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Hematology; OncologyProspective StudieBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Medicine (all); Hematology; OncologyImmunologySplenomegalyBCR-ABL PositiveBCR-ABL chronic myeloid leukemia prognosis tyrosine kinase inhibitors young adultsprognosisbusinessSpleenYoung adultsMyelogenous
researchProduct

Citrus limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death

2015

// Stefania Raimondo 1 , Flores Naselli 1 , Simona Fontana 1 , Francesca Monteleone 1 , Alessia Lo Dico 1 , Laura Saieva 1 , Giovanni Zito 2 , Anna Flugy 1 , Mauro Manno 3 , Maria Antonietta Di Bella 1 , Giacomo De Leo 1 , Riccardo Alessandro 1 1 Dipartimento di Biopatologia e Biotecnologie Mediche, Universita degli Studi di Palermo, sezione di Biologia e Genetica, Palermo, Italy 2 Laboratorio di Ingegneria Tissutale – Piattaforme Innovative per l’Ingegneria Tissutale (PON01–00829), Istituto Ortopedico Rizzoli, Palermo, Italy 3 Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Palermo, Italy Correspondence to: Riccardo Alessandro, e-mail: riccardo.alessandro@unipa.it Keywords: canc…

MaleProteomicsCitrusCell signalingProgrammed cell deathTime Factorsexosome-like nanovesiclesCell SurvivalCellApoptosisMice SCIDBiologyExosomesTNF-Related Apoptosis-Inducing LigandCitrus limon L.; TRAIL-mediated cell death; cancer; exosome-like nanovesiclesCitrus limon L.Mice Inbred NODCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositiveHuman Umbilical Vein Endothelial CellsmedicinecancerAnimalsHumansCell ProliferationPlant ProteinsPlants MedicinalPlant ExtractsCell growthCancermedicine.diseaseTRAIL-mediated cell deathAntineoplastic Agents PhytogenicXenograft Model Antitumor AssaysMicrovesiclesTumor BurdenFruit and Vegetable Juicesmedicine.anatomical_structureOncologyApoptosisImmunologyCancer researchNanoparticlesSignal transductionResearch PaperPhytotherapySignal Transduction
researchProduct

Carboxyamidotriazole-Orotate Inhibits the Growth of Imatinib-Resistant Chronic Myeloid Leukaemia Cells and Modulates Exosomes-Stimulated Angiogenesis

2012

The Bcr/Abl kinase has been targeted for the treatment of chronic myelogenous leukaemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML are often resistant. New therapeutic options are therefore needed for this fatal disease. Although more common in solid tumors, increased microvessel density was also reported in chronic myelogenous leukaemia and was associated with a significant increase of angiogenic factors, suggesting that vascularity in hematologic malignancies is a controlled process and may play a role in the leukaemogenic process thus representing an alternative therapeutic target. Carboxyamidotriazole-orotate (CTO) is …

MaleResearch ValidityPhysiologyAngiogenesisTumor PhysiologyFusion Proteins bcr-ablCancer Treatmentlcsh:MedicinePharmacologyExosomesCardiovascular PhysiologyBiochemistryPiperazinesHematologic Cancers and Related DisordersMicechemistry.chemical_compoundCell Movementhemic and lymphatic diseasesMolecular Cell BiologyBasic Cancer ResearchMedicine and Health SciencesPhosphorylationPost-Translational ModificationExtracellular Signal-Regulated MAP Kinaseslcsh:ScienceChronic Myelogenous LeukemiaMultidisciplinaryABLNeovascularization PathologicGene Expression Regulation LeukemicChemistryHematologyResearch AssessmentOncologyBenzamidesImatinib MesylateMedicineOncology AgentsAntiangiogenesis Therapymedicine.drugResearch ArticleChronic Myeloid LeukemiaAntineoplastic AgentsResearch and Analysis MethodsCell GrowthCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositiveLeukemiasCell AdhesionHuman Umbilical Vein Endothelial CellsmedicineAnimalsHumansRNA MessengerPhosphotyrosineBiologyCell ProliferationOrotic AcidTumor microenvironmentCarboxyamidotriazoleInterleukin-8lcsh:RBiology and Life SciencesProteinsCancers and NeoplasmsImatinibTriazolesmedicine.diseaseXenograft Model Antitumor AssaysRetractionExosomePyrimidinesImatinib mesylateDrug Resistance NeoplasmCarboxyamidotriazole Orotatelcsh:QAngiogenesisCell Adhesion MoleculesProto-Oncogene Proteins c-aktDevelopmental BiologyChronic myelogenous leukemiaPLoS ONE
researchProduct

Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid …

2007

BACKGROUND Despite advances in drug therapy and allogeneic stem cell transplantation (allo-SCT), the prognosis of patients with chronic myeloid leukemia (CML) in blast crisis remains poor. Imatinib has demonstrated synergistic effects in vitro with mitoxantrone, etoposide, and cytarabine. METHODS A Phase I/II trial was performed in patients with CML myeloid blast crisis. Patients were treated with imatinib + mitoxantrone/etoposide in four cohorts: mitoxantrone 10 mg/m2/day and etoposide 100 mg/m2/day for 2 or 3 consecutive days and imatinib 600 mg/day from Day 15 (cohorts 1 and 2) or from Day 1 (cohorts 3 and 4). After hematologic reconstitution after the cytopenic phase, cytarabine was giv…

OncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPharmacologyPiperazineshemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositiveAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansEtoposideAgedEtoposideMitoxantroneChemotherapybusiness.industryCytarabineMyeloid leukemiaImatinibMiddle AgedSurvival AnalysisTransplantationImatinib mesylatePyrimidinesTreatment OutcomeOncologyBenzamidesCytarabineImatinib MesylateFemaleMitoxantronebusinessBlast Crisismedicine.drugCancer
researchProduct

Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.

2020

OncologyAdultMalemedicine.medical_specialtyAdolescentMyelogenouschemistry.chemical_compoundInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositiveMedicineHumansChildProtein Kinase Inhibitorsbusiness.industryPonatinibLow doseFollow up studiesImidazolesMyeloid leukemiaInfantHematologymedicine.diseasePyridazinesLeukemiachemistryChild PreschoolFemalebusinessFollow-Up StudiesAmerican journal of hematology
researchProduct

Interferon-alpha combined with cytarabine in chronic myelogenous leukemia - clinical benefits.

2001

During the last decade, several studies have evaluated the treatment of chronic phase chronic myeloid leukemia (CML) with a combination of interferon (IFN)-alpha and low- dose cytarabine (Ara-C). This combination therapy has been shown to be superior compared to monotherapy with IFN-alpha in randomized studies with regard to hematologic and cytogenetic remissions. However, the survival benefit is small, and the toxicity of the combination therapy is high. This paper reviews the published studies on IFN-alpha/low-dose Ara-C for the treatment of chronic phase CML and discusses the value of the combination therapy.

OncologyCancer Researchmedicine.medical_specialtyCombination therapyAlpha interferonInterferonhemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositiveAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChronic phase CMLClinical Trials as Topicbusiness.industryCytarabineInterferon-alphaHematologymedicine.diseaseSurvival benefitOncologyToxicityCytarabinebusinessChronic myelogenous leukemiamedicine.drugLeukemialymphoma
researchProduct

Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.

2019

Discontinuation of tyrosine kinase inhibitors (TKIs) therapy is now feasible for patients with chronic myeloid leukemia (CML) with deep and longstanding molecular response (MR 4/4.5); around 40–60%...

OncologyDrugAdultMaleCancer Researchmedicine.medical_specialtymedia_common.quotation_subjectAntineoplastic AgentsDisease-Free Survival03 medical and health sciencesMyelogenous0302 clinical medicinehemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProtein Kinase Inhibitorsmedia_commonWithholding TreatmentDose-Response Relationship Drugbusiness.industryMyeloid leukemiaHematologyProtein-Tyrosine Kinasesmedicine.diseaseDiscontinuationLeukemiaPyrimidinesOncologyWithholding Treatment030220 oncology & carcinogenesisMolecular ResponseImatinib MesylateFemalebusinessTyrosine kinase030215 immunologyFollow-Up StudiesLeukemialymphoma
researchProduct

Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib

2020

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by neoplastic transformation of pluripotent cells due to a typical cytogenetic and molecular mutation known as Philadelphia (Ph) chromosome. In 2001, the introduction of the tyrosine kinasis inhibitor (TKI) imatinib as a therapeutic strategy for CML with PH chromosome mutation represented an important step towards treatment of these patients, and nowadays, this drug represents the gold therapeutic standard in this clinical setting. A second generation of TKIs (dasatinib, nilotinib, and bosutinib) showed an effective action in all patients with mutations resistant to imatinib. Ponatinib is a third-generation TKI an…

Oncologymedicine.medical_specialtyTyrosine kinase inhibitorReview030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicinemedicineHumansNeoplastic transformation030212 general & internal medicineProtein Kinase InhibitorsTyrosine kinase inhibitorsCardiotoxicitybusiness.industryPonatinibChronic myeloid leukemiaImidazolesDisease ManagementMyeloid leukemiaImatinibPyridazinesDasatinibCardio-oncologyEarly DiagnosisNilotinibchemistryCardiovascular DiseasesPonatinibPonatinib . Tyrosine kinase inhibitors . Chronic myeloid leukemia . Cardio-oncology . ReviewCardiology and Cardiovascular MedicinebusinessBosutinibFollow-Up Studiesmedicine.drug
researchProduct

Granulocytic sarcoma of the oral cavity in a chronic myeloid leukemia patient : an unusual presentation

2009

Intraoral granulocytic sarcoma is an unusual manifestation of chronic or acute leukemia. The oral manifestations often involve enlargements of the gingival and mucosal tissue from direct leukemic cell infiltration. Only 38 cases have been reported in scientific literature to date. We present the case of a 47 year-old female who was diagnosed with chronic myeloid leukemia (CML) in December 2006. She was referred to a dentist for further evaluation, revealing generalized gingival overgrowth as well as periodontal, apical disease, and bleeding of the gums. An oral biopsy was performed and histological features revealed immature blast-like cells.

Pathologymedicine.medical_specialtyDiseaseMyelogenousLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesBiopsyMedicineHumansSarcoma MyeloidGeneral DentistryAcute leukemiamedicine.diagnostic_testbusiness.industryMyeloid leukemiaMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]LeukemiaOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryFemaleMouth NeoplasmsSarcomabusinessInfiltration (medical)
researchProduct

Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.

2008

Although imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML), some patients develop resistance with progression of leukemia. Alternative or additional targeting of signaling pathways deregulated in bcr-abl-driven CML cells may provide a feasible option for improving clinical response and overcoming resistance. In this study, we show that carboxyamidotriazole (CAI), an orally bioavailable calcium influx and signal transduction inhibitor, is equally effective in inhibiting the proliferation and bcr-abl dependent- and independent-signaling pathways in imatinib-resistant CML cells. CAI inhibits phosphorylation of cellular proteins including STAT5 and CrkL a…

PhysiologyMAP Kinase Signaling SystemClinical BiochemistryFusion Proteins bcr-ablDown-RegulationApoptosisSignal transduction inhibitorPharmacologyPiperazineschemistry.chemical_compoundhemic and lymphatic diseasesCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansEnzyme InhibitorsPhosphotyrosineCMLneoplasmsIn Situ Hybridization FluorescenceChronic Myelogenous LeukemiaCell ProliferationCarboxyamidotriazolebusiness.industryCAIMyeloid leukemiaImatinibCell BiologyTriazolesmedicine.diseaseCRKLEnzyme ActivationGene Expression Regulation NeoplasticLeukemiaImatinib mesylatePyrimidineschemistryDrug Resistance NeoplasmMolecular ProbesBenzamidesimatinib resistanceImatinib Mesylateras ProteinsCML; imatinib resistance; CAICarboxyamidotriazolebusinesssignal transductionChronic myelogenous leukemiamedicine.drugJournal of cellular physiology
researchProduct